Multiple sclerosis is classified as an autoimmune disease by virtually every major medical organization and neurology textbook, and with good reason: the immune system attacks the myelin coating of nerve fibers in the brain and spinal cord, causing inflammation and lasting damage. But the label, while clinically useful, papers over a genuine scientific debate about what starts the process and why it keeps going. Researchers have spent decades arguing over whether the immune attack is truly the opening act or a reaction to something else going wrong inside the nervous system, and neither camp has fully settled the question.
The Case for Autoimmunity
The most direct evidence comes from the immune cells found in people with MS. T cells that react to myelin basic protein and proteolipid protein, two key components of the nerve-insulating myelin sheath, are far more common in MS patients than in people with other neurological conditions. Early research found these myelin-reactive T cells at concentrations several times higher in the blood of MS patients, and even more strikingly enriched in cerebrospinal fluid.1PubMed Central. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma More recent work has expanded the list of targets. A 2022 study identified four previously unreported protein targets that provoke T cell responses specifically in MS patients, including fatty acid-binding protein 7 and reticulon-3. The autoreactive profiles varied from person to person, but the responses were predominantly driven by a class of immune cells known as CD4+ T cells.2PubMed Central. Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis
The spinal fluid of MS patients tells a similar story from the antibody side. More than nine in ten people with established MS have oligoclonal bands, distinctive clusters of antibodies produced within the central nervous system that do not appear in the blood.3PubMed. Significance and stability of cerebrospinal fluid oligoclonal band patterns in multiple sclerosis These antibodies are considered the immunological hallmark of the disease.4PubMed Central. Oligoclonal IgG antibodies in multiple sclerosis target patient-specific peptides Their presence strongly suggests an ongoing, self-sustaining immune response inside the brain and spinal cord.
B cells, the immune cells responsible for producing antibodies, also play a broader role beyond just making oligoclonal bands. Activated B cells act as antigen-presenting cells that help switch on T cells, and they pump out inflammatory signaling molecules that amplify tissue damage.5PubMed Central. The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders This dual role, as both antibody factories and inflammatory instigators, helps explain why treatments that deplete B cells are so effective.
Why B Cell-Depleting Therapies Changed the Conversation
If MS were driven purely by T cells, you would not necessarily expect drugs that wipe out B cells to work so well. But they do. Anti-CD20 antibodies such as ocrelizumab, rituximab, and ofatumumab target a protein on the surface of B cells and destroy them. In head-to-head analyses, these drugs reduced relapse rates and outperformed older treatments without increasing serious side effects.6PubMed. The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis Ocrelizumab, for example, roughly halved the annual relapse rate compared to interferon beta-1a and more than doubled the odds of being relapse-free.7IBRO Neuroscience Reports. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: A network meta-analysis
The success of these therapies is arguably the strongest practical argument for calling MS an autoimmune disease. You suppress the immune attack and the disease slows. That said, B cell depletion works far better at preventing relapses than at stopping the slower, grinding disability that accumulates in later stages of the disease. That gap matters, and it is part of what keeps the debate alive.
The Epstein-Barr Virus Connection
One of the most significant developments in MS research over the past few years has been the strengthening link between Epstein-Barr virus, the pathogen that causes infectious mononucleosis, and the eventual development of MS. Epidemiological evidence now suggests EBV infection is essentially a prerequisite: nearly all MS patients have been infected, and the risk of developing MS after EBV infection is dramatically higher than in people who remain uninfected.8PubMed Central. Epstein-Barr virus and multiple sclerosis Researchers describe EBV as a “requisite risk factor,” meaning the disease appears not to develop without prior infection, even though the vast majority of people who catch EBV never develop MS.9PubMed Central. Epstein-Barr Virus in Multiple Sclerosis: Past, Present, and Future
The mechanistic piece of this puzzle came from a 2022 study that found molecular mimicry between an EBV protein called EBNA1 and a brain protein called GlialCAM. Antibodies the immune system made against the virus happened to cross-react with GlialCAM, effectively training the immune system to attack the brain’s own tissue.10PubMed Central. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM This is a textbook autoimmune mechanism: a virus tricks the immune system into mistaking self for non-self. But it also raises questions about where to draw the line between an infectious trigger and an autoimmune disease proper. If the initial immune misdirection is caused by a virus, is the disease itself autoimmune, or is it better understood as a downstream consequence of a viral infection?
Genetics Set the Stage
MS is not inherited in a straightforward way, but genetic susceptibility clearly plays a role, and the strongest genetic risk factor sits squarely in the immune system. A variant of the HLA-DRB1 gene called DRB1*1501 has been consistently linked to MS across nearly every population studied.11PubMed Central. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations HLA genes code for the proteins that display bits of other proteins to immune cells, essentially deciding which molecules the immune system learns to recognize. A variant in one of these genes increasing MS risk fits neatly with the autoimmune model: the wrong antigen presentation could lead to immune cells being primed against the body’s own myelin.
Beyond HLA, genome-wide studies have identified over two hundred additional risk variants for MS, and the vast majority are in or near genes involved in immune function. Environmental factors layer on top. Higher sun exposure and vitamin D levels are associated with lower MS severity and reduced relapse risk.12PubMed. Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity Lifetime ultraviolet radiation exposure also appears to reduce the risk of developing MS in the first place.13PubMed Central. Lifetime exposure to ultraviolet radiation and the risk of multiple sclerosis in the US radiologic technologists cohort study These findings are consistent with an immune-mediated disease, since vitamin D is known to influence immune regulation, though the exact pathways remain under investigation.
The “Inside-Out” Challenge
The standard model of MS, sometimes called the “outside-in” model, says the disease starts with an immune system gone haywire. Rogue immune cells cross the blood-brain barrier, attack myelin, and cause inflammation and nerve damage. But a competing hypothesis flips the sequence. The “inside-out” model proposes that something goes wrong inside the nervous system first, perhaps a subtle breakdown of myelin-producing cells called oligodendrocytes, and the immune attack is a secondary response to that initial damage.14PubMed Central. Pre-clinical and Clinical Implications of “Inside-Out” vs. “Outside-In” Paradigms in Multiple Sclerosis Etiopathogenesis
This is not a fringe idea. Experimental data show that oligodendrocyte death and myelin damage can precede and trigger the development of inflammation and autoimmune responses, rather than the other way around.15PubMed Central. The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis Mouse models in which oligodendrocyte death is induced by a toxin, without any immune provocation, can develop inflammatory demyelination that looks remarkably like MS. These findings raise a serious question: if the autoimmune response is secondary to nerve-cell death, then calling MS an autoimmune disease might be like calling a house fire a water-damage event because the fire trucks arrived.
One review put the implications bluntly: if the inside-out hypothesis is proven, MS could be viewed primarily as a neurodegenerative disease accompanied by a secondary inflammatory and autoimmune process.15PubMed Central. The Possible Role of Neural Cell Apoptosis in Multiple Sclerosis That would fundamentally change how the disease is understood and treated. Instead of focusing primarily on shutting down the immune system, treatment would need to prioritize protecting and repairing nerve cells.
The Neurodegeneration That Immunotherapy Cannot Reach
Even among researchers who accept the autoimmune classification, there is broad recognition that MS involves a neurodegenerative process that runs partly independent of the inflammatory attacks. This shows up clinically as disability that worsens steadily even in patients who have no relapses, a pattern now formalized as “progression independent of relapse activity,” or PIRA. PIRA is a significant contributor to long-term disability in relapsing-remitting MS.16PubMed. Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis The biology behind it includes slowly expanding lesions, gray matter shrinkage, persistent inflammation in the membranes surrounding the brain, and ongoing activation of the brain’s resident immune cells, microglia.17PubMed Central. Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis
In progressive MS, inflammation continues but it happens largely behind the blood-brain barrier, making it harder for drugs circulating in the bloodstream to reach the damage.18PubMed Central. Progressive multiple sclerosis: pathology and pathogenesis Iron-laden activated microglia accumulate at lesion borders and show up on MRI as paramagnetic rims, indicating ongoing tissue destruction.19PubMed Central. Demyelinated lesion associated compartmental inflammation in progressive multiple sclerosis brains Meanwhile, blood-brain barrier breakdown early in the disease allows harmful molecules and immune cells to flood into the nervous system, creating a self-reinforcing cycle of damage.20PubMed. Blood-brain barrier dysfunction in multiple sclerosis: causes, consequences, and potential effects of therapies
Neurofilament light chain, a structural protein released from damaged nerve fibers, has emerged as a blood-based biomarker that tracks this neurodegenerative component in real time. Higher levels predict worse future disability and faster brain and spinal cord shrinkage.21Brain. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis That neurofilament levels track nerve damage regardless of whether inflammation is the immediate cause makes it useful for measuring the parts of MS that anti-inflammatory drugs miss.22PubMed Central. Neurofilament Light Chain and Multiple Sclerosis: Building a Neurofoundational Model of Biomarkers and Diagnosis
Where MS Ends and Look-Alike Diseases Begin
Calling MS autoimmune sometimes creates confusion because other autoimmune diseases of the central nervous system can mimic it. Two in particular, aquaporin-4 neuromyelitis optica spectrum disorder (AQP4-NMOSD) and MOG antibody-associated disease (MOGAD), cause inflammation and demyelination in ways that can look similar on a basic MRI scan. Distinguishing them matters because the treatments differ and some MS drugs can worsen these other conditions.
Advanced imaging helps sort them out. MS lesions tend to have a distinctive central vein sign, a tiny vein running through the middle of each white-matter lesion, which is far more common in MS than in AQP4-NMOSD. Combining the central vein sign with cortical lesion counts and other measures can differentiate the two diseases with accuracy above 95%.23PubMed Central. Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With Imaging At the cellular level, the B cell populations driving each disease are different. MS appears to be driven more by memory B cells, while NMOSD involves a distinct subset called double-negative B cells and plasmablasts.24PubMed Central. Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation All three are autoimmune in the broad sense, but the specific immune pathways, antibody targets, and optimal treatments are different enough that lumping them together can lead to real harm.
The Animal Model Problem
Much of what we think we know about MS as an autoimmune disease comes from experimental autoimmune encephalomyelitis, or EAE, the most widely used animal model of the disease. EAE is created by deliberately provoking an immune attack against myelin in mice or rats, and it replicates several hallmark features of MS, including inflammation, demyelination, and nerve fiber damage.25Iranian Journal of Allergy, Asthma and Immunology. The Experimental Autoimmune Encephalomyelitis Model: A Gateway to Successful Translation of Multiple Sclerosis Therapies Multiple approved MS therapies were first tested in EAE models.26PubMed Central. Advantages and limitations of experimental autoimmune encephalomyelitis in breaking down the role of the gut microbiome in multiple sclerosis
The catch is that EAE is autoimmune by design. You inject the animal with myelin proteins to provoke the immune response. Treatments that work in EAE are, by definition, treatments that suppress an immune reaction that the researchers artificially created. This approach has been invaluable for understanding T cell-mediated damage and for developing anti-inflammatory drugs, but it has blind spots. No EAE model faithfully reproduces primary progressive MS, and the importance of cytotoxic CD8+ T cells in human MS has been consistently underestimated because most EAE protocols do not rely on them.27Brain. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research Relying heavily on an inherently autoimmune model naturally biases the field toward seeing MS through an autoimmune lens.
Mitochondria, the Gut, and the Drainage System
Several research threads have expanded the picture beyond pure autoimmunity. Sustained inflammation in MS leads to chronic oxidative stress that damages mitochondria, the energy-producing structures inside cells. Multiple independent studies have documented deficiencies in the mitochondrial respiratory chain and abnormal mitochondrial transport in MS, which may help explain why nerve fibers ultimately degenerate even after the acute inflammatory attack has passed.28PubMed Central. Mitochondrial Dysfunction and Multiple Sclerosis Whether mitochondrial dysfunction is a consequence of inflammation or an independent contributor to the disease remains an open question.
The gut microbiome has also entered the conversation. The community of bacteria in the intestines can modulate both the innate and adaptive immune systems, and alterations in gut flora have been linked to MS in both human and animal studies.29PubMed Central. Gut-Microbiota, and Multiple Sclerosis: Background, Evidence, and Perspectives This line of research is still early, but it adds to the sense that MS sits at an intersection of immune, metabolic, and environmental factors rather than fitting neatly into one box.
Even the brain’s waste-clearance system may be involved. The glymphatic system, which flushes fluid through the brain along blood-vessel pathways, appears to be impaired in MS. Researchers have speculated that sluggish glymphatic flow could promote inflammatory activation by allowing pro-inflammatory molecules to accumulate near vein walls, potentially triggering demyelination.30Brain. Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability It is another mechanism that does not start with a rogue immune cell but could still feed into the autoimmune cascade.
When Repair Fails
The brain has a built-in repair system for myelin damage. Cells called oligodendrocyte progenitor cells can generate new myelin-forming cells to patch up what the immune system destroys. In young, healthy tissue this remyelination process is highly efficient. But its effectiveness declines with age, and MS is a disease that often lasts decades.31PubMed Central. Remyelination and ageing: Reversing the ravages of time
Recent work has shown that in progressive MS, progenitor cells undergo cellular senescence, a state where they stop dividing and start secreting inflammatory signals instead of making new myelin. This senescence contributes directly to remyelination failure and, by extension, to the progressive disability that immune-targeting drugs have not been able to halt.32PubMed Central. Cellular senescence in progenitor cells contributes to diminished remyelination potential in progressive multiple sclerosis Reversing or preventing this age-related decline in progenitor-cell function is one of the most active areas of MS research. If therapies could maintain the brain’s repair capacity throughout the disease, the progressive phase might be slowed or even prevented, a goal that would complement immune suppression rather than replace it.
The practical upshot for people living with MS is that the autoimmune label, while accurate enough for understanding most current treatments, does not capture the full scope of the disease. Relapses driven by the immune system are one piece. Smoldering neurodegeneration, failing repair mechanisms, mitochondrial dysfunction, and age-related decline in brain plasticity are others. Future therapies will almost certainly need to address both sides of the equation.